MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Top Cited Papers
Open Access
- 1 March 2016
- journal article
- Published by Elsevier BV in Immunity
- Vol. 44 (3), 609-621
- https://doi.org/10.1016/j.immuni.2016.01.024
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- MEK and the inhibitors: from bench to bedsideJournal of Hematology & Oncology, 2013
- Progressive Loss of Memory T Cell Potential and Commitment to Exhaustion during Chronic Viral InfectionJournal of Virology, 2012
- Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic MelanomaCancer Research, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigensProceedings of the National Academy of Sciences of the United States of America, 2010
- The molecular signature of CD8+ T cells undergoing deletional toleranceBlood, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Signal transduction by lymphocyte antigen receptorsCell, 1994